US EditionPublished • loading... • Updated
Zentiva, a Leading European Generics Pharmaceutical Company, Announces Sale From Advent to GTCR
GTCR acquires Zentiva, a European generics leader with over 5,000 employees, marking a major private equity investment in healthcare amid growing market consolidation.
- On September 11, 2025, US private equity firm GTCR reached an agreement to purchase Zentiva, a Czech generics pharmaceutical company, from Advent International in a transaction valued at €4.1 billion.
- In 2018, Advent International purchased Zentiva from Sanofi for €1.9 billion and, after growing Zentiva’s range of products and manufacturing capabilities during a period of healthcare sector consolidation, decided to put the company up for sale.
- Zentiva operates in over 30 countries with more than 5,000 employees and has grown through organic expansion and acquisitions, serving millions of European patients with generics and OTC medicines.
- Zentiva CEO Steffen Saltofte praised Advent’s role in their growth, stating their investment in capabilities and pipeline was instrumental to serving millions across Europe.
- The sale marks a major European healthcare buyout and signals continued private equity interest in generics, with GTCR expected to maintain Zentiva’s growth and navigate market challenges.
Insights by Ground AI
14 Articles
14 Articles
Zentiva announces sale from Advent to GTCR
Zentiva, a leading European generics pharmaceutical company, Advent and GTCR – two leading global private equity investors – today announce the sale of Zentiva by Advent to GTCR. Since acquiring Zentiva from Sanofi in 2018, Advent has worked closely with the management team to successfully transform the business, whilst investing to expand Zentiva’s portfolio of medicines and manufacturing footprint, both organically and through targeted M&A. GT…
·Bucharest, Romania
Read Full ArticleCoverage Details
Total News Sources14
Leaning Left1Leaning Right1Center2Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 25%
C 50%
R 25%
Factuality
To view factuality data please Upgrade to Premium
